A naukri.com initiative
Bioengineer
2w
216
Image Credit: Bioengineer
Promising New Tablet Offers Hope for Controlling and Eradicating Intestinal Worms
- A clinical trial led by the Barcelona Institute of Global Health in collaboration with the STOP consortium has resulted in a significant breakthrough in the treatment of soil-transmitted helminthiases.
- The clinical trial introduced a tablet that combines albendazole and ivermectin, which is not only safe but is also more effective than the current standard treatment with albendazole alone, particularly in combating infections caused by Trichuris trichiura and other soil-transmitted helminths.
- Soil-transmitted helminthiases are parasitic infections caused by four major species of worms transmitted through contaminated soil and water, posing a considerable risk in Latin America, Asia, and sub-Saharan Africa.
- Albendazole has proven effective against Ascaris lumbricoides, but its efficacy against T. trichiura and S. stercoralis appears to be waning, potentially due to the emergence of drug resistance.
- The STOP consortium embarked on a ground-breaking clinical trial, funded by the European and Developing Countries Clinical Trials Partnership which aimed to evaluate a fixed-dose combination tablet containing both albendazole and ivermectin.
- The trial involved school-aged children diagnosed with T. trichiura, hookworms, or S. stercoralis and aimed to provide robust data on the safety and efficacy of the new treatment approach.
- The results of the trial revealed promising outcomes regarding efficacy, particularly against T. trichiura and hookworms. The fixed-dose combination achieved remarkable cure rates and showcased the superior efficacy of the fixed-dose combination when aligned with current treatment practices.
- The implications of this research extend far beyond a single trial, as they could pave the way for re-evaluating current elimination goals for STH and reshape public health policies on these neglected diseases that have long been regarded with a sense of inevitability in endemic regions.
- The innovative design of the Co-formulation focuses on easy administration, a critical characteristic for mass deworming campaigns aimed at vulnerable populations.
- The findings from the clinical trial point to a promising future in the fight against soil-transmitted helminthiases, highlighting the potential for a more effective and comprehensive approach to combating these neglected tropical diseases.
Read Full Article
13 Likes
For uninterrupted reading, download the app